HCG Share Price Performance
₹0
-510.10 (-100.00%)
Price ₹0
Fair Value₹773.71
Share Pricen/a
HealthCare Global Enterprises Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
HCG Community Narratives
AN
Fair Value ₹773.71 6.7% undervalued intrinsic discount
KKR's Entry Will Enable Expansion Of Precision Oncology And Fertility Services
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value ₹590 22.3% overvalued intrinsic discount
Rising Costs And Complexities Will Weaken Indian Oncology Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹857.76 15.9% undervalued intrinsic discount
Rising Indian NCD Burden And Urbanization Will Transform Oncology Care
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
KKR's Entry Will Enable Expansion Of Precision Oncology And Fertility Services
Key Takeaways Strategic moves, like KKR's entry and acquisitions, are expected to drive revenue growth through enhanced market reach and increased patient volumes. Emphasis on precision oncology and segment-focused restructuring aims to boost clinical outcomes, efficiency, and profitability, enhancing overall earnings performance.Read more
30
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
₹773.71
6.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
14.91% p.a.
Profit Margin
9.25%
Future PE
46.71x
Price in 2028
₹1.11k
Rising Indian NCD Burden And Urbanization Will Transform Oncology Care
Key Takeaways Access to KKR's expertise and capital, alongside strategic tech investment, could significantly accelerate HCG's expansion, operating leverage, and profitability beyond current forecasts. Rapid digital traction, precision oncology leadership, and increasing healthcare coverage may drive long-term market dominance and stronger, recurring revenue streams for HCG.Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹857.76
15.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
17.71% p.a.
Profit Margin
9.39%
Future PE
48.62x
Price in 2028
₹1.22k
Rising Costs And Complexities Will Weaken Indian Oncology Margins
Key Takeaways High capital investment and technology upgrades may pressure cash flow and margins if revenues don't keep up with rising costs and depreciation. Intensifying competition, regulatory changes, and staffing challenges threaten pricing power, patient volumes, and overall profitability.Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹590
22.3% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
15.62% p.a.
Profit Margin
8.97%
Future PE
36.95x
Price in 2028
₹842.44
Trending Discussion
Recently Updated Narratives
AN
HCG: Fair Outlook Will Reflect Margin Gains And Governance Developments
Fair Value: ₹773.71 6.7% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Costs And Complexities Will Weaken Indian Oncology Margins
Fair Value: ₹590 22.3% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Indian NCD Burden And Urbanization Will Transform Oncology Care
Fair Value: ₹857.76 15.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
HealthCare Global Enterprises Limited Key Details
About HCG
- Founded
- 1989
- Employees
- 6736
- CEO
- WebsiteView website
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
